Parkinson’s disease is one of the most common neurodegenerative diseases, second only to Alzheimer’s disease. It is estimated that over 4 million individuals worldwide suffer from the disease, and based on current estimates of its incidence and our growing aging population, that figure will likely double by 2030. Prevalence in the U.S. alone is estimated at 10.9 per 100,000 persons, but may be even higher due to misdiagnosis.
Parkinson’s Disease Research at the CTRND
At the CTRND, we are ideally positioned to research and to develop the next generation of novel therapies for Parkinson’s disease and related disorders. We have close ties to the the neurology and neuroscience departments, as well as the Movement Disorders & Neurorestoration Program at the Norman Fixel Institute for Neurological Diseases at UF Health. Although drugs and therapies are the goal, critical work begins here in the lab and at the bench where researchers try to understand the pathological mechanisms of these devastating diseases. Here the key to these disorders will be found.
The CTRND aims to be at the forefront of Parkinson’s research with a primary goal of understanding the contribution of genes and the environment to Parkinson’s disease. A better understanding of these factors will hopefully lead to development of biomarkers to detect and to help tract disease progression and to the development of potential novel therapeutics.